(PRESS RELEASE) PARIS, 29-Mar-2022 — /EuropaWire/ — Sanofi (EPA: SAN), a global biopharmaceutical company focused on human health, has announced that the company will provide an update on its Immunology strategy at its Immunology Investor Event, which is taking place … Read the full press release
Posted in France, Healthcare, News, Pharma & Biotech, Science, Technology
Tagged Bill Sibold, chronic inflammatory diseases, Chronic obstructive pulmonary disease, COPD, dupilumab, Dupixent, immunology, Immunology Investor Event, John Reed, NANOBODY®, Regeneron Pharmaceuticals, Sanofi, synthetic cytokines, Tailored Covalency®, type 2 inflammation
(PRESS RELEASE) CAMBRIDGE, 5-Jan-2021 — /EuropaWire/ — AstraZeneca (LON: AZN), a British-Swedish multinational pharmaceutical and biotechnology company, has announced the completion of the transfer of its global rights to Eklira (aclidinium bromide), popular as Tudorza in the US, and Duaklir … Read the full press release
Posted in Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Aclidinium bromide, Adrian Kemp, Almirall S.A., AstraZeneca, biopharmaceutical, Bretaris, Brimica, Chronic obstructive pulmonary disease, Covis Pharma, Covis Pharma Group, dry powder inhaler, Duaklir, Eklira, formoterol, Genuair, inhaled respiratory medicines, LABA, LAMA, muscarinic antagonist, Tudorza
Agreement sharpens AstraZeneca’s focus on priority medicines in Respiratory & Immunology portfolio (PRESS RELEASE) CAMBRIDGE, 1-Nov-2021 — /EuropaWire/ — AstraZeneca (LON: AZN), a British-Swedish multinational pharmaceutical and biotechnology company, has announced it sold the global rights of its chronic obstructive … Read the full press release
Posted in Business, Healthcare, Management, News, Pharma & Biotech
Tagged Aclidinium bromide, Almirall S.A., Alvesco, AstraZeneca, biopharmaceutical, Bretaris, Chronic obstructive pulmonary disease, COPD, Covis Pharma, Covis Pharma Group, Duaklir, Eklira, formoterol, Genuair, Genuair device, global rights, inhaler, LABA, LAMA, long-acting beta2-agonist, long-acting muscarinic antagonist, medicines, Omnaris, Pressair, respiratory medicines, rights, Tudorza, Zetonna
A thousand people are needed for ground-breaking research being carried out by the University of Birmingham into an incurable lung condition. BIRMINGHAM, 12-Jun-2018 — /EuropaWire/ — Supported by the British Lung Foundation, Dr Elizabeth Sapey and Professor Robert Stockley, will be … Read the full press release
LONDON, 20-Apr-2018 — /EuropaWire/ — Once-daily single inhaler triple therapy superior to Relvar/Breo Ellipta and Anoro Ellipta across multiple endpoints including exacerbations, lung function and quality of life. GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced the … Read the full press release
Philips joins COPD Foundation and family of late Leonard Nimoy in asking the world to #BreatheBoldly on social media to raise COPD awareness AMSTERDAM, 16-Nov-2016 — /EuropaWire/ — On World COPD Day, Royal Philips (NYSE: PHG, AEX: PHIA) is proud … Read the full press release
Your Time campaign calls for earlier action in COPD WHO expects COPD to be the third leading cause of death worldwide by 2030 – exceeded only by heart disease and stroke1 By the time most people know they have COPD, … Read the full press release
Posted in Germany, Healthcare, Society
Tagged Boehringer Ingelheim, Chronic obstructive pulmonary disease, COPD, Dr. Richard Russell
QVA149 improved lung function, breathlessness and health-related quality of life in moderate-to-severe COPD patients, according to EXPEDITION trial results[1]-[7] GEM 1 & 2 studies showed NVA237 provided significant and clinically meaningful improvements in lung function in moderate-to-severe COPD patients[8],[9] In … Read the full press release
Results are among key AstraZeneca respiratory data being presented at 2014 European Respiratory Society International Congress LONDON, 8-9-2014 — /EuropaWire/ — AstraZeneca today announced that The Lancet Respiratory Medicine has published encouraging safety and efficacy data from a Phase IIa … Read the full press release
London, 29-4-2014 — /EuropaWire/ — GlaxoSmithKline plc (LSE/NYSE: GSK) announced today that the European Commission has granted marketing authorisation for Incruse® (umeclidinium) as a once-daily, maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). Now licensed across … Read the full press release
Posted in Business, European Union, Healthcare, Marketing, Pharma & Biotech, United Kingdom
Tagged Chronic obstructive pulmonary disease, Darrell Baker, GlaxoSmithKline, GlaxoSmithKline's Incruse® (umeclidinium) gets European Commission marketing authorisation, Incruse® (umeclidinium), maintenance bronchodilator treatment of COPD
Most of the 64 million COPD patients around the world, including over 2 million in Spain, must contend with breathlessness, excessive mucus, chronic cough and other debilitating symptoms throughout 24hours a day The World Health Organization estimates that COPD kills … Read the full press release
21-5-2013 — /europawire.eu/ — Men experience a higher burden of disease and lower life expectancy than women, but policies focusing on the health needs of men are notably absent from the strategies of global health organisations, according to a Viewpoint article in this … Read the full press release
Posted in Healthcare, Society, United Kingdom
Tagged Cerebrovascular disease, Chronic obstructive pulmonary disease, Diarrhoeal diseases, disability, disease, disease on men, Global health policy, health policy, HIV/AIDS, Ischemic heart disease, Low back pain, Lower respiratory infections, malaria, premature death, Preterm birth complications, Road injury, University College London
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?
PHARMA & BIOTECH: The largest repository of EU/European pharma & biotech press releases spanning 12 years (2012-2024)
